ANITA DESWAL to Antineoplastic Agents
This is a "connection" page, showing publications ANITA DESWAL has written about Antineoplastic Agents.
Connection Strength
1.567
-
Time to Personalize Surveillance for Cancer Therapy-Related Cardiac Dysfunction in HER2-Targeted Therapy: One Size Does Not Fit All. Curr Heart Fail Rep. 2026 Jul 22; 23(1).
Score: 0.488
-
Myocardial Dysfunction in Patients with Cancer. Heart Fail Clin. 2022 Jul; 18(3):361-374.
Score: 0.368
-
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. J Clin Oncol. 2026 Aug; 44(22):2140-2155.
Score: 0.121
-
Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers. Cancer Med. 2026 Apr; 15(4):e71682.
Score: 0.119
-
Reevaluating Anti-Inflammatory Therapy: Targeting Senescence to Balance Anti-Cancer Efficacy and Vascular Disease. Arterioscler Thromb Vasc Biol. 2025 03; 45(3):372-385.
Score: 0.110
-
Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America. J Card Fail. 2025 02; 31(2):415-455.
Score: 0.108
-
SGLT2 Inhibitor Use and Risk of Clinical?Events in Patients With Cancer Therapy-Related Cardiac Dysfunction. JACC Heart Fail. 2024 01; 12(1):67-78.
Score: 0.101
-
Advances in Multimodality Imaging in?Cardio-Oncology: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 10 18; 80(16):1560-1578.
Score: 0.094
-
Tackling the Cardio-Kidney-Metabolic Burden in Cancer. Curr Atheroscler Rep. 2025 Sep 15; 27(1):92.
Score: 0.029
-
Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail. 2025 Nov; 27(11):2152-2167.
Score: 0.029